JP2023513220A - 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 - Google Patents

認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 Download PDF

Info

Publication number
JP2023513220A
JP2023513220A JP2022548088A JP2022548088A JP2023513220A JP 2023513220 A JP2023513220 A JP 2023513220A JP 2022548088 A JP2022548088 A JP 2022548088A JP 2022548088 A JP2022548088 A JP 2022548088A JP 2023513220 A JP2023513220 A JP 2023513220A
Authority
JP
Japan
Prior art keywords
subject
amyloid
months
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513220A5 (https=
Inventor
カタラノ、スーザン
ニコラス イゾ
Original Assignee
コグニション セラピューティクス インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コグニション セラピューティクス インク． filed Critical コグニション セラピューティクス インク．
Publication of JP2023513220A publication Critical patent/JP2023513220A/ja
Publication of JP2023513220A5 publication Critical patent/JP2023513220A5/ja
Priority to JP2025202377A priority Critical patent/JP2026041805A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022548088A 2020-02-13 2021-02-12 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 Pending JP2023513220A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025202377A JP2026041805A (ja) 2020-02-13 2025-11-24 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976325P 2020-02-13 2020-02-13
US62/976,325 2020-02-13
PCT/US2021/018023 WO2021163613A1 (en) 2020-02-13 2021-02-12 Method of decreasing amyloid beta monomer levels in patients with cognitive decline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025202377A Division JP2026041805A (ja) 2020-02-13 2025-11-24 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法

Publications (2)

Publication Number Publication Date
JP2023513220A true JP2023513220A (ja) 2023-03-30
JP2023513220A5 JP2023513220A5 (https=) 2024-02-19

Family

ID=77292728

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548088A Pending JP2023513220A (ja) 2020-02-13 2021-02-12 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法
JP2025202377A Pending JP2026041805A (ja) 2020-02-13 2025-11-24 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025202377A Pending JP2026041805A (ja) 2020-02-13 2025-11-24 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法

Country Status (8)

Country Link
US (1) US20230098944A1 (https=)
EP (1) EP4103604A4 (https=)
JP (2) JP2023513220A (https=)
KR (1) KR20220142477A (https=)
CN (1) CN115397849A (https=)
AU (1) AU2021218735A1 (https=)
IL (1) IL295427A (https=)
WO (1) WO2021163613A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
WO2024196799A2 (en) * 2023-03-17 2024-09-26 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用
WO2026030341A1 (en) * 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089988A1 (en) * 2017-11-01 2019-05-09 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
CA2611586A1 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
RU2692258C2 (ru) * 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
WO2018156883A1 (en) * 2017-02-23 2018-08-30 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
AU2019318888A1 (en) * 2018-08-07 2021-03-18 Sumitomo Pharma Co., Ltd. Diagnostic drug and diagnostic method for alzheimer's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089988A1 (en) * 2017-11-01 2019-05-09 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease

Also Published As

Publication number Publication date
CN115397849A (zh) 2022-11-25
US20230098944A1 (en) 2023-03-30
JP2026041805A (ja) 2026-03-10
WO2021163613A1 (en) 2021-08-19
EP4103604A1 (en) 2022-12-21
IL295427A (en) 2022-10-01
AU2021218735A1 (en) 2022-09-01
KR20220142477A (ko) 2022-10-21
EP4103604A4 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
JP2023513220A (ja) 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法
JP4767982B2 (ja) 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ−２５２ａ誘導体の使用
KR102188487B1 (ko) 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물
KR20160067103A (ko) 신경 장애를 치료하기 위한 토라세미드 및 바클로펜을 포함하는 조성물
US20170304289A1 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
AU2019443520A1 (en) A method of treating mental, behavioral, cognitive disorders
AU2016319107A1 (en) Methods of treating neurodegenerative disorders in a particular patient population
US20160310481A1 (en) Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders
JP2024533015A (ja) 脱髄性の疾患および病状の処置のためのフェンフルラミン
JP7849574B2 (ja) ゴーシェ病を処置するためのアリモクロモル
JP2007509920A (ja) 神経変性疾患の治療におけるヒドロキシム酸クロライドの使用
MX2015001888A (es) Laquinimod para tratamiento de trastornos mediados por ácido gamma-aminobutírico.
JP2021523126A (ja) 蓄積した病理学的Ｔａｕタンパク質を低減する方法
JPH1045582A (ja) アルツハイマー病の早期発病患者を治療するためのカルニチン誘導体を含む医薬
RU2841658C1 (ru) Способ снижения уровней мономеров бета-амилоида у пациентов со снижением когнитивных способностей
US20240050427A1 (en) Treatments for obsessive compulsive disorder
HK40083593A (en) Method of decreasing amyloid beta monomer levels in patients with cognitive decline
US20230301982A1 (en) N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of alzheimer's disease
US11957692B2 (en) Clomipramine for the treatment of Alzheimer's Disease
WO2025224600A1 (en) Treatment of alpha-synucleinopathies and neuroprotection
US20180133186A1 (en) Preventative treatment of alzheimer's disease
WO2025186837A1 (en) A synergistic bioactive composition for controlling neuromuscular pain and repairing nerve damage
CN118574810A (zh) 用尼罗加司他治疗卵巢癌
HK40050398A (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
HK40050398B (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260103